Analytical and Clinical Evaluation of the MeltArray Glioma Assay for Rapid Multiplex Detection of 18 Hotspot Mutations in FFPE Gliomas

Rapid hotspot mutation testing offers a practical route to integrated glioma diagnosis when tissue availability, turnaround time, or sequencing capacity is limited. We validated the MeltArray Glioma Assay, a laboratory-developed test that detects 18 hotspot mutations across IDH1, IDH2, TERT, histone H3 genes, and BRAF using only two reactions in a four-channel format. Analytical performance was assessed with respect to melting-temperature reproducibility, lowest tested detectable input, mutant allele fraction sensitivity, specificity, and the function of the RPP30 internal control. Assay calls in 168 formalin-fixed, paraffin-embedded gliomas were compared with targeted next-generation sequencing. Melting temperatures were highly reproducible across three independent SLAN-96S instruments of the same model (coefficients of variation, 0.07–0.48%). All 18 mutations were detected at 10 plasmid copies per reaction; at a total input of 1 × 105 plasmid copies per reaction, four mutations were detectable at a 0.1% mutant allele fraction and the remaining mutations at 0.5%. No target-specific melting peaks were observed with 293T cell or healthy-donor genomic DNA. In clinical specimens, the MeltArray assay classified 108 specimens as positive and 60 as negative, showing 100% positive, negative, and overall percentage agreement with sequencing. The 131 mutation events comprised 66 in TERT, 45 in IDH1/2, 10 in histone H3, and 10 in BRAF. The MeltArray assay enables rapid, sensitive hotspot genotyping on a standard four-channel real-time PCR platform and is best positioned as a focused adjunct to comprehensive molecular glioma classification.

Authors

Institutions

Publication Details

Journal
International Journal of Molecular Sciences
Published
2026-11-19
DOI
https://doi.org/10.3390/ijms272210443
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Analytical and Clinical Evaluation of the MeltArray Glioma Assay for Rapid Multiplex Detection of 18 Hotspot Mutations in FFPE Gliomas

Qiuying Huang, Qingge Li, Jitao Hai, Wuhao Lin et al.
International Journal of Molecular Sciences
Glioma Diagnosis and Treatment
article

Analytical and Clinical Evaluation of the MeltArray Glioma Assay for Rapid Multiplex Detection of 18 Hotspot Mutations in FFPE Gliomas

Qiuying Huang, Qingge Li, Jitao Hai, Wuhao Lin, Boheng Xu, Wei Ni, Yan Wang, Zhiyao Liu
article en

Abstract

Rapid hotspot mutation testing offers a practical route to integrated glioma diagnosis when tissue availability, turnaround time, or sequencing capacity is limited. We validated the MeltArray Glioma Assay, a laboratory-developed test that detects 18 hotspot mutations across IDH1, IDH2, TERT, histone H3 genes, and BRAF using only two reactions in a four-channel format. Analytical performance was assessed with respect to melting-temperature reproducibility, lowest tested detectable input, mutant allele fraction sensitivity, specificity, and the function of the RPP30 internal control. Assay calls in 168 formalin-fixed, paraffin-embedded gliomas were compared with targeted next-generation sequencing. Melting temperatures were highly reproducible across three independent SLAN-96S instruments of the same model (coefficients of variation, 0.07–0.48%). All 18 mutations were detected at 10 plasmid copies per reaction; at a total input of 1 × 105 plasmid copies per reaction, four mutations were detectable at a 0.1% mutant allele fraction and the remaining mutations at 0.5%. No target-specific melting peaks were observed with 293T cell or healthy-donor genomic DNA. In clinical specimens, the MeltArray assay classified 108 specimens as positive and 60 as negative, showing 100% positive, negative, and overall percentage agreement with sequencing. The 131 mutation events comprised 66 in TERT, 45 in IDH1/2, 10 in histone H3, and 10 in BRAF. The MeltArray assay enables rapid, sensitive hotspot genotyping on a standard four-channel real-time PCR platform and is best positioned as a focused adjunct to comprehensive molecular glioma classification.

International Journal of Molecular SciencesVol. 27(22)
Xiamen University (CN), Sun Yat-sen University Cancer Center (CN), State Key Laboratory of Oncology in South China (CN)
Glioma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon